Clarus Therapeutics Holdings, Inc. is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women – including potential therapies for orphan indications. Clarus Therapeutics’ first commercial product is JATENZO®.
Company profile
Ticker
CRXTQ
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Blue Water Acquisition Corp.
SEC CIK
Corporate docs
IRS number
851231852
CRXTQ stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
7 Mar 23
EFFECT
Notice of effectiveness
7 Mar 23
EFFECT
Notice of effectiveness
7 Mar 23
EFFECT
Notice of effectiveness
7 Mar 23
15-12G
Securities registration termination
1 Mar 23
8-K
Bankruptcy or Receivership
1 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Mar 23
POS AM
Prospectus update (post-effective amendment)
1 Mar 23
POS AM
Prospectus update (post-effective amendment)
1 Mar 23
POS AM
Prospectus update (post-effective amendment)
1 Mar 23
Latest ownership filings
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 23
SC 13G/A
Bracebridge Capital, LLC
6 Jul 22
4
MARK A PRYGOCKI SR
9 Jun 22
4
Kimberly M Murphy
9 Jun 22
4
John Kenneth Amory
9 Jun 22
4
Joseph Hernandez
9 Jun 22
4
Elizabeth Cermak
9 Jun 22
4
Joseph Hernandez
27 Apr 22
4/A
JAMES E THOMAS
25 Apr 22
SC 13D/A
Thomas, McNerney & Partners, LLC
22 Apr 22
Financial summary
Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 19.17 mm | 19.17 mm | 19.17 mm | 19.17 mm | 19.17 mm | 19.17 mm |
Cash burn (monthly) | (no burn) | (no burn) | 3.56 mm | 3.44 mm | 3.66 mm | 2.97 mm |
Cash used (since last report) | n/a | n/a | 78.03 mm | 75.27 mm | 80.05 mm | 65.12 mm |
Cash remaining | n/a | n/a | -58.85 mm | -56.10 mm | -60.87 mm | -45.94 mm |
Runway (months of cash) | n/a | n/a | -16.5 | -16.3 | -16.6 | -15.4 |
Institutional ownership, Q2 2022
27.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 28 |
Opened positions | 12 |
Closed positions | 1 |
Increased positions | 8 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 91.38 mm |
Total shares | 14.35 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
H.I.G.-GPII | 5.69 mm | $54.82 mm |
CBC SPVI | 3.60 mm | $34.69 mm |
Bracebridge Capital | 2.00 mm | $761.00 k |
Vanguard | 1.04 mm | $397.00 k |
BLK Blackrock | 323.80 k | $124.00 k |
Geode Capital Management | 301.65 k | $115.00 k |
CVI Investments | 264.41 k | $0.00 |
Sabby Management | 200.00 k | $76.00 k |
VIRT Virtu Financial | 188.09 k | $72.00 k |
Millennium Management | 170.52 k | $65.00 k |